Thought Leadership
Overview China Reflections NewslettersOp-eds North Head in the World
China Healthcare Outlook - 2017 Issue 3
Email Print

The Chinese government made significant progresses regarding market access of pharmaceutical and medical devices. Both the Ministry of Human Resources and Social Security (MOHRSS) and the China Food and Drug Administration (CFDA) released important exposure drafts on reimbursement and registration, marking a milestone of the Chinese healthcare reform. Noteworthy policy items were the release of:

*  State Council released 2017 Work Foci to Deepen Healthcare Reform
*  MOST released the Special Plan for the 13th Five-Year Plan for Biotechnology Innovation
*  MOHRSS seeks public opinions on how to establish a dynamic adjustment mechanism for NRDL
*  CFDA released new regulations on clinical trial, registration, administration and intellectual property of pharmaceutical and medical devices (exposure drafts)
*  CFDA released Administrative Measures of Medical Devices Standards

 

China Healthcare Outlook - 2017 Issue 3